Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients

Mise à jour : Il y a 4 ans
Référence : NCT00280917

Femme et Homme

Extrait

This trial will test the hypothesis that the addition of CF101, a novel anti-inflammatory agent, will improve the clinical condition of patients with rheumatoid arthritis who still have active joint inflammation despite taking methotrexate for at least 6 months.


Critère d'inclusion

  • Rheumatoid Arthritis


Liens